1. Home
  2. INCY vs IOT Comparison

INCY vs IOT Comparison

Compare INCY & IOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$120.67

Market Cap

23.7B

Sector

Health Care

ML Signal

N/A

Logo Samsara Inc.

IOT

Samsara Inc.

N/A

Current Price

$42.21

Market Cap

23.3B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
INCY
IOT
Founded
1991
2015
Country
United States
United States
Employees
2844
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
23.7B
23.3B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
INCY
IOT
Price
$120.67
$42.21
Analyst Decision
Buy
Buy
Analyst Count
28
26
Target Price
★ $130.63
$52.07
AVG Volume (30 Days)
1.8M
★ 3.9M
Earning Date
10-29-2026
12-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 4173.33
92.86
EPS
★ 0.50
0.10
Revenue
★ $3,394,635,000.00
$1,618,635,000.00
Revenue This Year
$18.06
$26.37
Revenue Next Year
$3.30
$20.02
P/E Ratio
★ $79.26
$414.80
Revenue Growth
13.67
★ 29.57
52 Week Low
$89.25
$23.38
52 Week High
$132.60
$47.47

Technical Indicators

Market Signals
Indicator
INCY
IOT
Relative Strength Index (RSI) 56.42 50.71
Support Level $115.77 $36.52
Resistance Level $130.53 $42.96
Average True Range (ATR) 3.63 1.98
MACD 0.95 -0.10
Stochastic Oscillator 79.39 45.72

Price Performance

Historical Comparison
INCY
IOT

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

About IOT Samsara Inc.

Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers range from small and medium-sized businesses to state and local governments.

Share on Social Networks: